ctDNA Guided Adjuvant Treatment With Elacestrant: TBCRC-068

"Administration of elacestrant will follow the FDA approved dose and schedule for patients with ER+ metastatic breast cancer. Elacestrant 345 mg will be administered orally once daily for 12 cycles or until disease progression or unacceptable toxicity. The pills shall be administered with food (to reduce nausea and vomiting) at approximately the same time each day, and the prescription will be provided with the standard Swallow tablets whole; do not chew, crush, or split warning label."